Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy. - Wikidata - wikimedia - TriplyDB

Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy.

Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy.

http://www.wikidata.org/entity/Q39481822

about

Recent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and Imaging Nanoparticle-based targeted therapeutics in head-and-neck cancer Micelle-like nanoparticles as carriers for DNA and siRNA Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance.Molecular-targeted nanotherapies in cancer: enabling treatment specificity.Recent advances in delivery of drug-nucleic acid combinations for cancer treatment Adjuvanted influenza vaccines.Non-Viral Delivery and Therapeutic Application of Small Interfering RNAs.Materials innovation for co-delivery of diverse therapeutic cargos.Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents.Tackling breast cancer chemoresistance with nano-formulated siRNA.Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells.Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems.Advanced materials for co-delivery of drugs and genes in cancer therapy.Recent progress in multidrug delivery to cancer cells by liposomes.Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy.Efficacy of DOPE/DC-cholesterol liposomes and GCPQ micelles as AZD6244 nanocarriers in a 3D colorectal cancer in vitro model.Codelivery of paclitaxel and small interfering RNA by octadecyl quaternized carboxymethyl chitosan-modified cationic liposome for combined cancer therapy.

P2860

Q26778234-42DEE878-CA8D-493D-8723-41870230F9AB Q26999699-815D9EAC-21B0-4CF2-9D44-74605584885B Q27001558-2283FA0A-0D5F-431E-B4A9-6493BAB4CB8C Q28073956-6D8E2C30-32F0-45A7-9EE7-3CAD8E9271E3 Q28818166-23B2D75F-3DCA-4EC9-8E1B-CF6C61AF3890 Q30456053-359A2E7C-BB7B-4F25-8AB8-DBDCFE834624 Q33859472-B6F0A1AE-C352-4E87-89EF-FCEC660B4A13 Q34622662-B6A7E24F-D9FC-4D35-8470-140C8EE6D181 Q35924301-59516A10-655E-44AD-B4A1-EC419193CEF1 Q37954497-FC2AC0BF-A9E8-47B9-A11B-260FA80D0D47 Q38102522-7BFBCED8-E43F-4952-9689-A40E25128784 Q38140045-94C42724-81D5-4447-AD92-E3B521DB1302 Q38168518-6B544B8F-F4A2-4E84-B97A-50B3405F59B8 Q38211033-35D229FB-B6BA-46FD-A384-AAE42ABE9DB6 Q38555082-75619CAE-E647-4BCF-9B14-3B716929506B Q38959517-6C9CDFB5-95A0-4DA8-89EA-FC1348081878 Q39187136-B49FC0BA-2C98-4921-B170-563CA3DA94E5 Q39317565-58D311A9-C52C-42A7-B2C3-39955E99825C Q39513734-21B7FD7C-24A4-442B-B843-54881A1926C2 Q44874958-BA1FB67F-979A-4A37-BD1E-8C363FA4E372 Q52649904-BEE1FFBF-B6C3-4B1C-882C-3C9E333086CE Q52888231-8E27A075-E761-4917-9F2F-614C0DD8D853 Q53272796-39A1FAD2-75D2-4EB3-AB12-2111C7F95BE5

P2860

Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy.

http://www.wikidata.org/entity/Q39481822

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Cationic liposomal co-delivery ...... enhanced anticancer efficacy.

@en

Cationic liposomal co-delivery ...... enhanced anticancer efficacy.

@nl

type

label

Cationic liposomal co-delivery ...... enhanced anticancer efficacy.

@en

Cationic liposomal co-delivery ...... enhanced anticancer efficacy.

@nl

prefLabel

Cationic liposomal co-delivery ...... enhanced anticancer efficacy.

@en

Cationic liposomal co-delivery ...... enhanced anticancer efficacy.

@nl

P1433

Q39481822-7A510DCC-E5CC-4E78-8DFB-329D3C230C40

P1476

Q39481822-B2B04EEC-4ABB-435E-B6CD-B2070A44C6E3

P2093

Q39481822-1D9334E4-9C03-4231-AF17-F5633FAC59EE

Q39481822-7BE1AE58-A6F8-4C22-A69A-2567C7FAFC89

Q39481822-A7974AC8-2AEF-483B-B93B-C4850D5F12E7

Q39481822-C7224AC1-33B3-41A1-B65F-CBF43AB9C5FC

Q39481822-D5154FB9-7F26-4281-A66C-4BA0FF64A0A0

Q39481822-D541928D-5314-4299-8793-51EFA6207C35

Q39481822-E2C13EF5-F335-4D83-AB0D-F9ACBB408D02

Q39481822-EAD44361-35D1-4534-AF0E-C9DF295DEFD4

P2860

Q39481822-1201E6B0-2EED-47C2-A27E-F965053C2CBF

Q39481822-13FEC986-18FF-4C25-9BED-DD9E562F9B5F

Q39481822-15F65EC7-24D4-4C13-A3DC-5601C5E4B9D5

Q39481822-2ABB1DDA-B4D0-47BE-AF60-4B4E174C955A

Q39481822-339B5EF7-4785-48FE-807B-1F6DD51EF4C7

Q39481822-49E4E062-8ADE-456D-AFCF-8D77328F77EC

Q39481822-5FD52EF2-61A9-49A9-9714-B6C6ABA76060

Q39481822-62DDDA51-7C6D-4EC3-BABD-E3FBE4FC083B

Q39481822-756BB1D4-358D-492A-A095-EC63C054DF5B

Q39481822-7D9DD49E-FA15-490F-96CC-D4F12412395F

P304

Q39481822-1AC56257-6541-4075-9CA7-B2F2DBB5609B

P31

Q39481822-D881D455-F5DC-4275-860D-0EBC7F2649A5

P356

Q39481822-84C97991-B65A-4E90-A5BE-4CAD24025705

P433

Q39481822-CD9AFAD9-D1D6-4125-AFF6-8907A6CAFD62

P478

Q39481822-6F670575-62E9-4B4A-8795-D4A9F64F0DEA

P577

Q39481822-B074B617-BBCD-46D0-BDB6-978DE63FE134

P5875

Q39481822-C673593B-5290-46E0-AAD3-ADF8176D4983

P698

Q39481822-B43C5142-96FD-48FB-969D-99CA4B1CC78F

P356

S11095-011-0569-4

P1433

Pharmaceutical Research

P1476

Cationic liposomal co-delivery ...... enhanced anticancer efficacy.

@en

P2093

Chan-Wha Kim

http://www.w3.org/2001/XMLSchema#string

Gayong Shim

http://www.w3.org/2001/XMLSchema#string

Han-Gon Choi

http://www.w3.org/2001/XMLSchema#string

Hee-Jeong Cho

http://www.w3.org/2001/XMLSchema#string

Sangbin Lee

http://www.w3.org/2001/XMLSchema#string

Seung Hee Kang

http://www.w3.org/2001/XMLSchema#string

Su-Hyeon Kim

http://www.w3.org/2001/XMLSchema#string

Yu-Kyoung Oh

http://www.w3.org/2001/XMLSchema#string

P2860

The Bcl-2 apoptotic switch in cancer development and therapy

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers.

Anionic amino acid-derived cationic lipid for siRNA delivery.

Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells

Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer.

MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo

Clinical experience of MEK inhibitors in cancer therapy.

Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations.

P304

3069-3078

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11095-011-0569-4

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51607152

http://www.w3.org/2001/XMLSchema#string

P698

21879387

http://www.w3.org/2001/XMLSchema#string